Alterity Therapeutics Gets Positive FDA Feedback On ATH434 Phase 3 Study
27/4 14:16
(RTTNews) - Alterity Therapeutics Limited (ATHE) on Monday said it received positive feedback from the U.S. Food and Drug Administration following a Type C meeting regarding its planned Phase 3 program for ATH434 in Multiple System Atrophy (MSA)....